REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental drug boosts Cancer-Killing cells in lymphoma trial
Disease control OngoingThis early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC